GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BriaCell Therapeutics Corp (TSX:BCT) » Definitions » Equity-to-Asset
中文

BriaCell Therapeutics (TSX:BCT) Equity-to-Asset

: -0.66 (As of Jan. 2024)
View and export this data going back to 2006. Start your Free Trial

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. BriaCell Therapeutics's Total Stockholders Equity for the quarter that ended in Jan. 2024 was C$-10.84 Mil. BriaCell Therapeutics's Total Assets for the quarter that ended in Jan. 2024 was C$16.42 Mil.

The historical rank and industry rank for BriaCell Therapeutics's Equity-to-Asset or its related term are showing as below:

TSX:BCT' s Equity-to-Asset Range Over the Past 10 Years
Min: -7.94   Med: 0.47   Max: 1
Current: -0.66

During the past 13 years, the highest Equity to Asset Ratio of BriaCell Therapeutics was 1.00. The lowest was -7.94. And the median was 0.47.

TSX:BCT's Equity-to-Asset is ranked worse than
90.73% of 1564 companies
in the Biotechnology industry
Industry Median: 0.66 vs TSX:BCT: -0.66

BriaCell Therapeutics Equity-to-Asset Historical Data

The historical data trend for BriaCell Therapeutics's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BriaCell Therapeutics Annual Data
Trend Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.55 -6.89 0.48 0.24 -0.14

BriaCell Therapeutics Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.04 -0.20 -0.14 0.15 -0.66

Competitive Comparison

For the Biotechnology subindustry, BriaCell Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BriaCell Therapeutics Equity-to-Asset Distribution

For the Biotechnology industry and Healthcare sector, BriaCell Therapeutics's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where BriaCell Therapeutics's Equity-to-Asset falls into.



BriaCell Therapeutics Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

BriaCell Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Jul. 2023 is calculated as

Equity to Asset (A: Jul. 2023 )=Total Stockholders Equity/Total Assets
=-4.99/35.886
=

BriaCell Therapeutics's Equity to Asset Ratio for the quarter that ended in Jan. 2024 is calculated as

Equity to Asset (Q: Jan. 2024 )=Total Stockholders Equity/Total Assets
=-10.836/16.418
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BriaCell Therapeutics  (TSX:BCT) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


BriaCell Therapeutics Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of BriaCell Therapeutics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


BriaCell Therapeutics (TSX:BCT) Business Description

Traded in Other Exchanges
Address
235 - 15th Street, Suite 300, West Vancouver, 3rd Floor, Bellevue Centre, Vancouver, BC, CAN, V7T 2X1
BriaCell Therapeutics Corp is an immuno-oncology-focused biotechnology company. The group develops targeted and safe approaches for the management of cancer. BriaCell is conducting a Phase I/IIa clinical trial of Bria-IMT in metastatic breast cancer. Additionally, it is developing Bria-OTS, off-the-shelf personalized immunotherapy, for the treatment of advance-stage breast cancer by matching the patient's HLA type.

BriaCell Therapeutics (TSX:BCT) Headlines

No Headlines